Skip to main content
Signal8

POAI (POAI)

Predictive Oncology Inc. logo

Predictive Oncology Inc.

NASDAQ:POAIHealthcare
Mkt Cap-
Float8.54M
O/S-
Inst Own-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--
SectorHealthcare
IndustryMedical - Instruments & Supplies
ExchangeNASDAQ
CountryUSUS
IPO DateMay 3, 2010
Shares Outstanding-
Float8.54M
Company Overview

Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States.

The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics division offers extensive clinical diagnostic services, including tumor drug response assessments and genomic profiling, alongside contract research focused on patient-centered drug discovery. This latter service leverages active learning technology for foundational discovery, clinical and translational research, clinical trials, and the development and validation of diagnostics. Meanwhile, the zPREDICTA division excels in crafting organ-specific disease models, providing three-dimensional reconstructions of human tissues that accurately mirror various disease states and simulate drug responses, particularly for evaluating anticancer agents. The Soluble segment delivers services centered on High-Throughput Self-Interaction Chromatography, an automated system proficient at screening additives and excipients in protein formulations to ensure the creation of soluble and physically stable biologic therapeutics. This segment also provides protein stability analysis, specialized kits for swift identification of soluble formulations, and proprietary technologies for the detection and elimination of bacterial endotoxins. The Skyline division markets the STREAMWAY System, a fully automated, wall-mounted device designed to substantially minimize healthcare staff's exposure to blood and other infectious fluids in clinical environments. Furthermore, this division conducts research and development and supplies specialized media that supports the ex-vivo growth of cancer cells while maintaining their original DNA/RNA and proteomic signatures. Founded in 2002, the company was formerly known as Precision Therapeutics Inc. until it adopted the name Predictive Oncology Inc. in June 2019.

Its corporate headquarters are situated in Eagan, Minnesota.

Leadership

Chuck Nuzum

Director

Daniel E. Handley, M.S., Ph.D.

Director

Gregory S. St. Clair, Sr.

Director

Josh Blacher

Chief Financial Officer

Employees

23

Country

US

Sector

Healthcare

Website

predictive-oncology.com

Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
No price targets available
Ratings Distribution
BUY
0
HOLD
1
SELL
0
TOTAL1
Insider Trades
InsiderTypeShares
Blacher Joshua profile photoBlacher JoshuaGrant/Award9.4K
Vennare Raymond F profile photoVennare Raymond FAutomatic Sell2.4K
Hawryluk Matthew profile photoHawryluk MatthewGrant/Award64.7K
Rao Veena profile photoRao VeenaGrant/Award64.7K
Blacher Joshua profile photoBlacher JoshuaGrant/Award97.0K
Vennare Raymond F profile photoVennare Raymond FGrant/Award125.0K
Shareholders
--
Institutional
(26)
--
Insiderⓘ
(13)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Sources: 13F, Form 4, 13D/13G
Insiders & Institutional Holders
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...